Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Escalating Single Doses of ENV8058 in Healthy Subjects
NCT02153099Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-058 in schizophrenia (7 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event at Day 30, Percentage of Participants With Markedly Abnormal Safety Laboratory Tests at Day 14 and 1 more. Started Jun 2014; status: completed.
02
Drugs
TAK-058
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02153099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153099.